Chantal Morel is a health economist specialising in issues related to antimicrobial resistance (AMR). Her research examines the costs imposed by AMR and the use of interventions to reduce the overall economic burden. This includes interventions at the point of prescribing (incentives to improve stewardship) in both human and animal settings. It also looks at the use of new financing and structural arrangements to bolster innovation in the antibiotic pipeline to produce better products, improve surveillance of resistance, broaden system-wide sustainable use measures, and increase access to antibiotics where there is clinical need currently unmet by supply.
